Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.
作者信息
Rubio Miguel A
机构信息
Servicio de Endocrinología y Nutrición, Hospital Clínico San Carlos, Madrid, España.
出版信息
Endocrinol Nutr. 2014 Dec;61(10):501-4. doi: 10.1016/j.endonu.2014.11.002.
PMID:25434595
Abstract
摘要
相似文献
1
Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.
Endocrinol Nutr. 2014 Dec;61(10):501-4. doi: 10.1016/j.endonu.2014.11.002.
2
Nonincretin drugs in later-stage development.
Am J Manag Care. 2014 Jan;20(1 Spec No.):E2.
3
New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
Cardiol Rev. 2014 Jan-Feb;22(1):43-50. doi: 10.1097/CRD.0000000000000001.
4
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
Expert Opin Drug Saf. 2017 Jan;16(1):27-39. doi: 10.1080/14740338.2017.1247807. Epub 2016 Oct 24.
5
Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.
Drugs Today (Barc). 2011 Dec;47(12):903-14. doi: 10.1358/dot.2011.47.12.1718738.
6
Two new drugs approved for obesity.
S D Med. 2012 Sep;65(9):356-7.
7
Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1777-801. doi: 10.1586/erc.10.125. Epub 2010 Aug 16.
8
Pharmacotherapy for obesity: What you need to know.
Cleve Clin J Med. 2017 Dec;84(12):951-958. doi: 10.3949/ccjm.84a.16094.
9
Practical Use of Pharmacotherapy for Obesity.
Gastroenterology. 2017 May;152(7):1765-1779. doi: 10.1053/j.gastro.2016.12.049. Epub 2017 Feb 10.
10
The FDA's assessment of two drugs for chronic weight management.
N Engl J Med. 2012 Oct 25;367(17):1577-9. doi: 10.1056/NEJMp1211277. Epub 2012 Oct 10.
Zotero 插件